where to inject a glp 1 The 3 Most Common GLP-1 Injection Sites Where you inject matters more

In a snapshot of monthly transitions, only 2 percent of compounded patients move to branded products

While tirzepatide has yet to demonstrate direct cardiovascular risk outcomes in patients without type 2 diabetes, tirzepatide-treated groups did demonstrate reductions in cardiometabolic variables resulting in a significantly lower 10-year predicted ASCVD risk in patients with overweight or obesity without type 2 diabetes in post hoc analysis of the SURMOUNT-1 trial [49]

On average, they suffered from type 2 diabetes for 12 years, but this varied greatly among participants

Tirzepatide also showed improvements in lipids and cardiovascular risk factors compared to dulaglutide 1.5 mg and placebo